Ferreri AJM, Calimeri T, Cwynarski K, et al. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023;9(1):29. https://doi.org/10.1038/s41572-023-00439-0.

Article  PubMed  PubMed Central  Google Scholar 

Khoury JD, Solary E, Abla O, et al. The 5th edition of the organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19.

Article  PubMed  PubMed Central  Google Scholar 

Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–6. https://doi.org/10.1182/blood-2005-03-1024.

Article  PubMed  CAS  Google Scholar 

Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58(10):1513–20. https://doi.org/10.1212/wnl.58.10.1513.

Article  PubMed  CAS  Google Scholar 

Montesinos-Rongen M, Brunn A, Bentink S, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia. 2008;22(2):400–5. https://doi.org/10.1038/sj.leu.2405019.

Article  PubMed  CAS  Google Scholar 

Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687–94. https://doi.org/10.1093/neuonc/nox187.

Article  PubMed  Google Scholar 

Houillier C, Soussain C, Ghesquieres H, et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 2020;94(10):e1027–39. https://doi.org/10.1212/WNL.0000000000008900.

Article  PubMed  PubMed Central  Google Scholar 

Ferreri AJM, Cwynarski K, Pulczynski E, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022;36(7):1870–8. https://doi.org/10.1038/s41375-022-01582-5.

Article  PubMed  CAS  Google Scholar 

Houillier C, Dureau S, Taillandier L, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study. J Clin Oncol. 2022;40(32):3692–8. https://doi.org/10.1200/JCO.22.00491.

Article  PubMed  CAS  Google Scholar 

Tringale KR, Scordo M, Yahalom J, et al. Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphoma. Blood Adv. 2024;8(24):6195–206. https://doi.org/10.1182/bloodadvances.2024013780.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17. https://doi.org/10.1016/0360-3016(92)90538-s.

Article  PubMed  CAS  Google Scholar 

Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6(8):650–61 (https://pubmed.ncbi.nlm.nih.gov/17667956).

Article  PubMed  CAS  Google Scholar 

O’Neill BP, Wang CH, O’Fallon JR, et al. Primary central nervous system non-Hodgkin’s lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86–72-52. Int J Radiat Oncol Biol Phys. 1999;43(3):559–63. https://doi.org/10.1016/s0360-3016(98)00450-7.

Article  PubMed  CAS  Google Scholar 

Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88–06. J Clin Oncol. 1996;14(2):556–64. https://doi.org/10.1200/JCO.1996.14.2.556.

Article  PubMed  CAS  Google Scholar 

Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys. 2001;51(2):419–25. https://doi.org/10.1016/s0360-3016(01)01639-x.

Article  PubMed  CAS  Google Scholar 

Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18(17):3144–50. https://doi.org/10.1200/JCO.2000.18.17.3144.

Article  PubMed  CAS  Google Scholar 

Batchelor T, Carson K, O’Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J Clin Oncol. 2003;21(6):1044–9. https://doi.org/10.1200/JCO.2003.03.036.

Article  PubMed  CAS  Google Scholar 

Skarin AT, Zuckerman KS, Pitman SW, et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977;50(6):1039–47 (https://www.ncbi.nlm.nih.gov/pubmed/303529).

PubMed  CAS  Google Scholar 

Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11(2):211–5. https://doi.org/10.1215/15228517-2008-067.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20. https://doi.org/10.1016/S0140-6736(09)61416-1.

Article  PubMed  CAS  Google Scholar 

Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510–23. https://doi.org/10.1016/S2352-3026(17)30174-6.

Article  PubMed  Google Scholar 

Schmitt AM, Herbrand AK, Fox CP, et al. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis. Hematol Oncol. 2019;37(5):548–57. https://doi.org/10.1002/hon.2666.

Article  PubMed  CAS  Google Scholar 

Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47. https://doi.org/10.1016/S1470-2045(10)70229-1.

Article  PubMed  CAS  Google Scholar 

DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635–43. https://doi.org/10.1200/JCO.1992.10.4.635.

Article  PubMed  CAS  Google Scholar 

O’Brien PC, Roos DE, Pratt G, et al. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys. 2006;64(2):408–13. https://doi.org/10.1016/j.ijrobp.2005.07.958.

Article  PubMed  Google Scholar 

Bessell EM, Graus F, Lopez-Guillermo A, et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2001;50(2):457–64. https://doi.org/10.1016/s0360-3016(01)01451-1.

Article  PubMed  CAS  Google Scholar 

Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21(24):4483–8. https://doi.org/10.1200/JCO.2003.03.108.

Article  PubMed  CAS  Google Scholar